SpectraWave has secured $50 million in a Series B funding round it will use to advance commercial expansion and product additions to the company’s HyperVue Imaging System, which has 510(k) clearance from the U.S. Food and Drug Administration (FDA).
HyperVue combines SpectraWave's DeepOCT and NIRS technology to optimize image quality and procedural efficiency in the cath lab, it said. These tools allow for no-flush catheter prep, fast and long pullbacks designed to reduce and remove the use of contrast, and an AI-driven workflow and image analysis offering.
The funding round was led by Johnson & Johnson Innovation-JJDC and joined by S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, and Heartwork Capital, among others.
